`J7530` Mycophenolat (myhibbin) 5 mg

Mycophenolate mofetil (myhibbin), oral suspension, 5 mg

Medicare coverage: Carrier judgment
Status: active (October 2026 file)

Medicare pricing for J7530

Medicare Part B drug payment limit (ASP, October 2026)

J7530 payment limit: $0.115 per 5 MG, effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data. Coinsurance 18.875%. Note: Added October 2026 - Inflation-adjusted coinsurance.

NDCs that bill under J7530 (CMS ASP NDC-HCPCS crosswalk, October 2026)

24338-0018-01 Myhibbin, Azurity Pharmaceuticals, Inc.: 7000 billing units per package (1 BOTTLE, PLASTIC in 1 CARTON / 175 mL in 1 BOTTLE, PLASTIC)

Physician Fee Schedule (CY 2026, RVU26D)

Status E: excluded from the PFS by regulation.

Payer policies and prior authorization for J7530

1 of 1 payer prior-auth lists that name J7530 require prior authorization or set conditions: Humana.

Payer	Plan	State	Prior auth	Conditions	Since	Source
Humana	Humana Healthy Horizons	OK	prior auth required		Oct 14, 2026	Humana Healthy Horizons in Oklahoma Prior Authorization and Notification List

Recent prior-auth changes

Oct 14, 2026: PA added, Humana

From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.

J7530 Mycophenolat (myhibbin) 5 mg